160 related articles for article (PubMed ID: 27124418)
1. Early phase mixed chimerism in bone marrow does not affect long-term outcomes of myeloablative single-unit cord blood transplantation for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Dec; 57(12):2848-2854. PubMed ID: 27124418
[TBL] [Abstract][Full Text] [Related]
2. Complete donor T cell chimerism predicts lower relapse incidence after standard double umbilical cord blood reduced-intensity conditioning regimen allogeneic transplantation in adults.
Peterlin P; Delaunay J; Guillaume T; Gastinne T; Mahé B; Dubruille V; Blin N; Le Bourgeois A; Brissot E; Lodé L; Le Gouill S; Moreau P; Mohty M; Chevallier P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):180-4. PubMed ID: 25175796
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
[TBL] [Abstract][Full Text] [Related]
4. Reduced-intensity conditioning followed by unrelated umbilical cord blood transplantation for advanced hematologic malignancies: rapid engraftment in bone marrow.
Misawa M; Kai S; Okada M; Nakajima T; Nomura K; Wakae T; Toda A; Itoi H; Takatsuka H; Itsukuma T; Nishioka K; Fujimori Y; Ogawa H; Hara H
Int J Hematol; 2006 Jan; 83(1):74-9. PubMed ID: 16443557
[TBL] [Abstract][Full Text] [Related]
5. Impact of hematopoietic chimerism at day +14 on engraftment after unrelated donor umbilical cord blood transplantation for hematologic malignancies.
Moscardó F; Sanz J; Senent L; Cantero S; de la Rubia J; Montesinos P; Planelles D; Lorenzo I; Cervera J; Palau J; Sanz MA; Sanz GF
Haematologica; 2009 Jun; 94(6):827-32. PubMed ID: 19483157
[TBL] [Abstract][Full Text] [Related]
6. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
7. Effect of ABO blood group incompatibility on the outcome of single-unit cord blood transplantation after myeloablative conditioning.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Apr; 20(4):577-81. PubMed ID: 24368297
[TBL] [Abstract][Full Text] [Related]
8. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival.
Koreth J; Kim HT; Nikiforow S; Milford EL; Armand P; Cutler C; Glotzbecker B; Ho VT; Antin JH; Soiffer RJ; Ritz J; Alyea EP
Biol Blood Marrow Transplant; 2014 Oct; 20(10):1516-21. PubMed ID: 24907627
[TBL] [Abstract][Full Text] [Related]
9. Comparable long-term outcome of unrelated cord blood transplantation with related bone marrow or peripheral blood stem cell transplantation in patients aged 45 years or older with hematologic malignancies after myeloablative conditioning.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Kawamata T; Tojo A; Takahashi S
Biol Blood Marrow Transplant; 2014 Aug; 20(8):1150-5. PubMed ID: 24727335
[TBL] [Abstract][Full Text] [Related]
10. Rapid induction of single donor chimerism after double umbilical cord blood transplantation preceded by reduced intensity conditioning: results of the HOVON 106 phase II study.
Somers JA; Braakman E; van der Holt B; Petersen EJ; Marijt EW; Huisman C; Sintnicolaas K; Oudshoorn M; Groenendijk-Sijnke ME; Brand A; Cornelissen JJ
Haematologica; 2014 Nov; 99(11):1753-61. PubMed ID: 25107890
[TBL] [Abstract][Full Text] [Related]
11. Chimerism and minimal residual disease monitoring after reduced intensity conditioning (RIC) allogeneic transplantation.
Pérez-Simón JA; Caballero D; Diez-Campelo M; Lopez-Pérez R; Mateos G; Cañizo C; Vazquez L; Vidriales B; Mateos MV; Gonzalez M; San Miguel JF
Leukemia; 2002 Aug; 16(8):1423-31. PubMed ID: 12145680
[TBL] [Abstract][Full Text] [Related]
12. Better outcomes of modified myeloablative conditioning without antithymocyte globulin versus myeloablative conditioning in cord blood transplantation for hematological malignancies: A retrospective (development) and a prospective (validation) study.
Sun Z; Liu H; Luo C; Geng L; Zheng C; Tang B; Zhu X; Tong J; Wang X; Ding K; Wan X; Zhang L; Yao W; Song K; Zhang X; Wu Y; Yang H; Han Y; Liu X; Zhu W; Wu J; Wang Z
Int J Cancer; 2018 Aug; 143(3):699-708. PubMed ID: 29473150
[TBL] [Abstract][Full Text] [Related]
13. Impact of sex incompatibility on the outcome of single-unit cord blood transplantation for adult patients with hematological malignancies.
Konuma T; Kato S; Ooi J; Oiwa-Monna M; Ebihara Y; Mochizuki S; Yuji K; Ohno N; Kawamata T; Jo N; Yokoyama K; Uchimaru K; Tojo A; Takahashi S
Bone Marrow Transplant; 2014 May; 49(5):634-9. PubMed ID: 24535130
[TBL] [Abstract][Full Text] [Related]
14. Successful allogeneic stem cell transplantation with nonmyeloablative conditioning in patients with relapsed hematologic malignancy following autologous stem cell transplantation.
Dey BR; McAfee S; Sackstein R; Colby C; Saidman S; Weymouth D; Poliquin C; Vanderklish J; Sachs DH; Sykes M; Spitzer TR
Biol Blood Marrow Transplant; 2001; 7(11):604-12. PubMed ID: 11760148
[TBL] [Abstract][Full Text] [Related]
15. Comparison of graft-versus-host disease-free, relapse-free survival of transplantation using matched sibling donor, matched unrelated donor or unrelated cord blood after myeloablative conditioning for adult patients with hematological malignancies.
Konuma T; Kato S; Oiwa-Monna M; Ishii H; Tojo A; Takahashi S
Leuk Lymphoma; 2016 Sep; 57(9):2126-32. PubMed ID: 26769297
[TBL] [Abstract][Full Text] [Related]
16. Adjusted conditioning for allogeneic transplantation in a single center setting: mixed chimerism heralds relapse.
Juliusson G; Karlsson K; Malm C; Frödin U; Mollén AS; Bäckström G; Söderkvist P
Leuk Lymphoma; 2003 Apr; 44(4):669-79. PubMed ID: 12769345
[TBL] [Abstract][Full Text] [Related]
17. Analysis of donor-type chimerism in lineage-specific cell populations after allogeneic myeloablative and non-myeloablative stem cell transplantation.
Miura Y; Tanaka J; Toubai T; Tsutsumi Y; Kato N; Hirate D; Kaji M; Sugita J; Shigematsu A; Iwao N; Ota S; Masauzi N; Fukuhara T; Kasai M; Asaka M; Imamura M
Bone Marrow Transplant; 2006 May; 37(9):837-43. PubMed ID: 16547484
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
19. Donor Lymphocyte Infusions Used to Treat Mixed-Chimeric and High-Risk Patient Populations in the Relapsed and Nonrelapsed Settings after Allogeneic Transplantation for Hematologic Malignancies Are Associated with High Five-Year Survival if Persistent Full Donor Chimerism Is Obtained or Maintained.
Caldemeyer LE; Akard LP; Edwards JR; Tandra A; Wagenknecht DR; Dugan MJ
Biol Blood Marrow Transplant; 2017 Nov; 23(11):1989-1997. PubMed ID: 28712934
[TBL] [Abstract][Full Text] [Related]
20. Donor/recipient mixed chimerism does not predict graft failure in children with beta-thalassemia given an allogeneic cord blood transplant from an HLA-identical sibling.
Lisini D; Zecca M; Giorgiani G; Montagna D; Cristantielli R; Labirio M; Grignani P; Previderè C; Di Cesare-Merlone A; Amendola G; Bergami E; Mastronuzzi A; Maccario R; Locatelli F
Haematologica; 2008 Dec; 93(12):1859-67. PubMed ID: 18945748
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
